Welcome to our dedicated page for ROCKET PHARMACEUTICALS SEC filings (Ticker: RCKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ROCKET PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ROCKET PHARMACEUTICALS's regulatory disclosures and financial reporting.
Rocket Pharmaceuticals insider Martin Wilson sold 12,109 shares of common stock on 08/14/2025 at $3.019 per share to satisfy tax withholding arising from the vesting of restricted stock units (RSUs). After the sale, the reporting person beneficially owned 137,054 shares. The Form 4 lists Mr. Wilson as General Counsel and an officer of the issuer and is signed on 08/18/2025.
Form 144 filing for Rocket Pharmaceuticals, Inc. (RCKT) shows a proposed sale of 1,004 common shares through Fidelity Brokerage Services with an aggregate market value of $3,077.46, planned for 08/18/2025 on NASDAQ. The shares were acquired by the filer on 08/14/2025 through restricted stock vesting as compensation. The filing also discloses two recent sales by the same person in the prior three months: 587 shares sold on 05/20/2025 for $3,783.80 and 12,109 shares sold on 08/14/2025 for $36,553.44. The notice includes the signer’s representation that they are not aware of undisclosed material adverse information about the issuer.
Form 144 notice for Rocket Pharmaceuticals, Inc. (RCKT): The filing notifies a proposed sale of 699 common shares through Fidelity Brokerage Services LLC on 08/18/2025, with an aggregate market value of $2,142.57. The shares were acquired by the seller via restricted stock vesting on 08/14/2025 and were issued as compensation. The filing also reports sales by the same person earlier this year: 357 shares sold on 05/20/2025 for $2,301.22 and 7,043 shares sold on 08/14/2025 for $21,260.70. The issuers outstanding shares are listed as 107,903,871.
Form 144 filed for Rocket Pharmaceuticals, Inc. (RCKT) reports a proposed sale of 1,680 common shares through Fidelity Brokerage Services on 08/18/2025 with an aggregate market value of $5,149.54. The filing shows these shares were acquired on 08/14/2025 via restricted stock vesting and paid as compensation. The issuer's outstanding share count is listed as 107,903,871. The filer previously sold 801 shares on 05/20/2025 for $5,163.25 and 11,161 shares on 08/14/2025 for $33,691.71. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 for Rocket Pharmaceuticals, Inc. (RCKT) reports a proposed sale of 7,043 common shares through Fidelity Brokerage Services with an approximate aggregate market value of $21,260.70, and an approximate sale date of 08/14/2025 on NASDAQ. These shares were acquired on 08/12/2025 by restricted stock vesting from the issuer as compensation. The filing lists total shares outstanding of 107,903,871.
The notice also discloses two prior sales by the same person during the past three months: 655 shares on 05/16/2025 for $4,275.51 and 357 shares on 05/20/2025 for $2,301.22. The filer affirms they are not aware of any undisclosed material adverse information about the issuer.
Rocket Pharmaceuticals, Inc. (RCKT) Form 144 notifies a proposed sale of 12,109 common shares (aggregate market value $36,553.44) to be sold on or about 08/14/2025 on NASDAQ. The shares were acquired by vesting of restricted stock from the issuer on 08/12/2025 and were paid as compensation. The filing also discloses two recent sales by Martin Wilson of 946 and 587 shares on 05/16/2025 and 05/20/2025, generating gross proceeds of $6,175.02 and $3,783.80 respectively. The document shows the total shares outstanding as 107,903,871. Several standard filer contact and signature fields appear blank in the provided content.
Form 144 notice for proposed sale of common stock tied to restricted stock vesting. The filing shows 11,161 shares of Common stock to be sold through Fidelity Brokerage Services LLC on 08/14/2025 with an aggregate market value of $33,691.71. The shares were acquired on 08/12/2025 as Restricted Stock Vesting and paid as Compensation. The filer who sold shares in the past three months is identified as Jonathan D. Schwartz, with two prior sales on 05/16/2025 (1,582 shares for $10,326.51) and 05/20/2025 (801 shares for $5,163.25). The filing lists the issuer-related fields but does not provide the issuer name or address in the supplied content.
The filing also reports 107,903,871 shares outstanding, which makes the proposed sale approximately 0.0103% of outstanding shares based on provided figures.
Rocket Pharmaceuticals disclosure shows that Maverick-affiliated entities and Lee S. Ainslie beneficially hold 8,363,813 shares of common stock, equal to 7.8% of the company based on 107,737,919 shares outstanding. The reported holdings arise from multiple funds and accounts: Maverick Fund USA, Ltd. (1,686,548 shares); Maverick Fund II, Ltd. (1,727,675); Maverick Long Enhanced Fund, Ltd. (1,930,078); Maverick HP, L.P. (1,726,954); Maverick Long Fund, Ltd. (958,547); and separately managed accounts (334,011).
Maverick is identified as the investment adviser with investment discretion over these client accounts, Maverick Capital Management is the general partner, and Lee S. Ainslie III is the manager. The filing reports no sole voting or dispositive power and shared voting and dispositive power over all 8,363,813 shares, indicating a significant institutional stake without unilateral control.
Item 2.02: On August 7, 2025 Rocket Pharmaceuticals, Inc. announced preliminary financial information for the quarter ended June 30, 2025 via a press release furnished as Exhibit 99.1. The filing states the exhibit is furnished, not filed under Item 2.02 and therefore not subject to Section 18 liability.
Item 5.02: Effective December 31, 2025, Dr. Kinnari Patel will leave the Company to join RTW Investments LP as a venture partner. As of August 8, 2025 she no longer serves as President, Head of Research and Development and will assist in transitioning her duties to other executives. Exhibits include the press release (99.1) and Inline XBRL cover page (104). The report is signed by Martin Wilson on August 7, 2025.